Literature DB >> 33176262

Performance characteristics of the SpeeDx PlexPCR VHS assay for the molecular detection of herpes simplex virus, varicella zoster virus, and Treponema pallidum in lesion swabs.

Emily J Goldstein1, Lauren Cochrane2, Simon M Bone3, Rory N Gunson2.   

Abstract

This study compares the performance of a commercial polymerase chain reaction (PCR) assay for detection of herpes simplex virus (HSV) 1 and 2, varicella zoster virus (VZV), and Treponema pallidum with laboratory-developed assays. A panel of 250 samples, previously tested using in-house assays, was tested on the PlexPCR® VHS assay. The panel consisted of 202 positive specimens [HSV-1 (n=51); HSV-2 (n=51); VZV (n=51); T. pallidum (n=49)] and 48 negative specimens. Genital samples had been previously tested for HSV-1/2 and T. pallidum and nongenital or unspecified samples for HSV-1/2 and VZV. The overall agreement between the PlexPCR® VHS and in-house assays was 97%. Negative agreement was ≥99%, and positive agreement for individual targets was 96% (47/49) for T. pallidum, 98% for HSV-1 and HSV-2 (50/51), and 100% (51/51) for VZV. Adoption of this assay would allow greater availability of molecular syphilis detection and enhance the diagnostic yield of samples collected from cutaneous/mucocutaneous lesions.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  HSV; Real-time PCR; Sexually transmitted infections; Syphilis; VZV

Mesh:

Year:  2020        PMID: 33176262     DOI: 10.1016/j.diagmicrobio.2020.115221

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  1 in total

1.  Nonclassical Pathogens as Causative Agents of Proctitis in Men who Have Sex With Men.

Authors:  Eric P F Chow; Darren Lee; Stephanie Bond; Christopher K Fairley; Kate Maddaford; Rebecca Wigan; Glenda Fehler; Sigrid A Lange; Vesna De Petra; Melanie Bissessor; Catriona S Bradshaw; Benjamin P Howden; Jane S Hocking; Deborah A Williamson; Marcus Y Chen
Journal:  Open Forum Infect Dis       Date:  2021-03-19       Impact factor: 3.835

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.